HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ...

1 Press Release HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology — Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Phase III registration part ...

(RTTNews) - HUTCHMED (China) Ltd. (HCM), a commercial-stage biopharmaceutical company, is scheduled to present new and updated data from its ESLIM-01 Phase III trial at the American Society of ...

(RTTNews) - HUTCHMED (China) Ltd. (HCM) on Wednesday announced that Phase III registration part of its ESLIM-02 clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the ...

- plans for regulatory submission underway in china, where it was designated a breakthrough therapy - - results to be submitted to an upcoming medical meeting - hong kong and shanghai, china and ...

The safety profile of sovleplenib in ESLIM-01 was consistent with previously reported studies. The majority of treatment-emergent adverse events (“TEAEs”) were mild or moderate in severity (grade 1 or ...

— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- ...